Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4345 - Influence of an international consensus conference on practice patterns in advanced prostate cancer (APC)

Date

10 Sep 2017

Session

Poster display session

Presenters

Jun Gong

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

J. Gong1, S.K. Pal1, J. Hsu1, B. Tombal2, M.R. Sydes3, A. Omlin4, S. Gillessen5

Author affiliations

  • 1 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 2 Urology, Cancer Centre, Catholic University of Louvain (UCL), 1200 - Brussels/BE
  • 3 Mcr Clinical Trials Unit, Institute of Clinical Trials and Methodology-UCL, WC2B6NH - London/GB
  • 4 Oncology And Haematology, Cantonal Hospital St.Gallen , St. Gallen/CH
  • 5 Oncology/hematology  , Kantonsspital St. Gallen, 9007 - St. Gallen/CH
More

Resources

Abstract 4345

Background

Development of several agents and combinations in metastatic castrate-naïve (mCN) and castration-resistant (mCR) PC has led to uncertainty in best management approaches. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 convened to provide expert opinions on open questions.

Methods

57 questions (Qs) selected from a sample of consensus Qs to be voted on at APCCC 2017 were administered as a pre- and post-conference survey to attendees. Matched responses before and after APCCC 2017 were compared to identify changes in attendees’ treatment preferences in APC.

Results

From 2/2017-4/2017, pre- and post-conference surveys from 120 attendees were collected mostly from medical oncologists (41.7%) and urologists (40.8%). Attendees reached a consensus ≥75% vote in the same pre- and post-meeting question in 10/57 Qs (15.7%). A 

Conclusions

To the best of our knowledge, we are among the first to compare pre- and post-meeting responses that highlight interesting changes in provider preferences in APC management. Consensus conferences such as APCCC where expert opinions are discussed provide a unique learning experience and delineate key areas of controversy in APC where further study is needed.

Clinical trial identification

Legal entity responsible for the study

The Advanced Prostate Cancer Consensus Conference

Funding

The Advanced Prostate Cancer Consensus Conference

Disclosure

S.K. Pal: Honoraria: Novartis, Medivation, Astellas Pharma Consulting or Advisory Role: Pfizer, Novartis, Aveo, Myriad Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma Research Funding: Medivation. B. Tombal: Funding: Astellas, Bayer, Ferring, Ipsen, Sanofi-Aventis Honoraria: Amgen, Astellas, Bayer, Medivation, Ferring, Ipsen, Sanofi-Aventis Speaker's Bureau: Amgen, Astellas, Bayer, Medivation, Ferring, Ipsen, Sanofi-Aventis. M.R. Sydes: Research Support: Astellas, Janssen, Novartis, Pfizer, Sanofi-Aventis. A. Omlin: Advisory role (compensated, institutional): Astellas, Bayer, Sanofi, Roche, Janssen Research support (institutional): Teva, Janssen Travel support: Astellas, Bayer, Sanofi, Roche. S. Gillessen: Advisory Boards: AAA International, Active Biotech AB IDMC, Astellas, Bayer, Bristol-Myers Squibb, Curevac, Dendreon, Ferring, GlaxoSmithKline, Janssen Cilag, MaxiVAX SA, Millenium Pharmaceuticals, Novartis, Pfizer, Orion, Roche, Sanofi-Aventis. All other authors have declared no conflicts of interest.

Disclosure

S.K. Pal: Honoraria: Novartis, Medivation, Astellas Pharma Consulting or Advisory Role: Pfizer, Novartis, Aveo, Myriad Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma Research Funding: Medivation. B. Tombal: Funding: Astellas, Bayer, Ferring, Ipsen, Sanofi-Aventis Honoraria: Amgen, Astellas, Bayer, Medivation, Ferring, Ipsen, Sanofi-Aventis Speaker\'s Bureau: Amgen, Astellas, Bayer, Medivation, Ferring, Ipsen, Sanofi-Aventis. M.R. Sydes: Research Support: Astellas, Janssen, Novartis, Pfizer, Sanofi-Aventis. A. Omlin: Advisory role (compensated, institutional): Astellas, Bayer, Sanofi, Roche, Janssen Research support (institutional): Teva, Janssen Travel support: Astellas, Bayer, Sanofi, Roche. S. Gillessen: Advisory Boards: AAA International, Active Biotech AB IDMC, Astellas, Bayer, Bristol-Myers Squibb, Curevac, Dendreon, Ferring, GlaxoSmithKline, Janssen Cilag, MaxiVAX SA, Millenium Pharmaceuticals, Novartis, Pfizer, Orion, Roche, Sanofi-Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.